

# Funded vaccines for special groups from 1 August 2021

For specific eligibility details, please refer to individual vaccines on the Pharmaceutical Schedule ([www.pharmac.govt.nz](http://www.pharmac.govt.nz)).

For vaccine administration schedules, please refer to the online *Immunisation Handbook* or relevant IMAC fact sheet ([www.immune.org.nz/resources/written-resources](http://www.immune.org.nz/resources/written-resources)).

|   |  |
|---|--|
| Adolescents and young people 13–25 years inclusively entering specified close-living situations   | <ul style="list-style-type: none"> <li>• Meningococcal vaccine</li> </ul>  |
| Asplenia – Functional or Pre- or Post-Splenectomy<br><small>IMAC fact sheet available</small>   | <ul style="list-style-type: none"> <li>• Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines</li> </ul>   |
| Chemotherapy – following <small>IMAC fact sheet available</small>   | <ul style="list-style-type: none"> <li>• Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul>  |
| » Also consider immunosuppression for longer than 28 days   | <ul style="list-style-type: none"> <li>• Hepatitis B and meningococcal vaccines</li> </ul>   |
| Cochlear implant  | <ul style="list-style-type: none"> <li>• Hib, influenza, and pneumococcal vaccines</li> </ul>  |
| Error of metabolism at risk of major metabolic decompensation   | <ul style="list-style-type: none"> <li>• Influenza and varicella vaccines</li> </ul>   |
| Haematopoietic stem cell transplantation (HSCT) – following<br><small>IMAC fact sheet available</small>   | <ul style="list-style-type: none"> <li>• Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul>                             |
| » Also consider immunosuppression for longer than 28 days   | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>  |
| Hepatitis A case – contact with   | <ul style="list-style-type: none"> <li>• Hepatitis A vaccine</li> </ul>  |
| Hepatitis B case – contact with   | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth</li> </ul>   |
| » Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive  |  |
| » Household and sexual contacts of known acute hepatitis B cases or carriers  | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>  |
| Hepatitis C positive  | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>  |
| HIV positive  | <ul style="list-style-type: none"> <li>• Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines</li> </ul>                           |
| Immunocompromised   |  |
| » Household contacts of children or adults who will be/are immunosuppressed   | <ul style="list-style-type: none"> <li>• Varicella vaccine</li> </ul>  |
| » Elective immunosuppression for longer than 28 days<br><small>IMAC fact sheet available</small>  | <ul style="list-style-type: none"> <li>• Varicella (prior to immunosuppression only), hepatitis B, Hib, influenza, meningococcal, and Tdap vaccines</li> </ul> |
| » Immunodeficiency – primary or secondary   | <ul style="list-style-type: none"> <li>• Hib, influenza, meningococcal, and pneumococcal vaccines</li> </ul>   |
| Influenza Immunisation Programme  |  |
| » Pregnancy   |  |
| » Individuals aged 65 years or older  |  |
| » Individuals aged 6 months to under 65 years with an eligible medical condition  |  |
| » Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness | <ul style="list-style-type: none"> <li>• Influenza vaccine</li> </ul>  |
| Kidney disease <small>IMAC fact sheet available</small>   | <ul style="list-style-type: none"> <li>• Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul>                                    |
| Liver disease   | <ul style="list-style-type: none"> <li>• Hepatitis A and varicella vaccines</li> </ul>   |
| Meningococcal disease case – contact with   | <ul style="list-style-type: none"> <li>• Meningococcal vaccine</li> </ul>  |
| Needle stick injury – following   | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>  |
| Non-consensual sexual intercourse – following   | <ul style="list-style-type: none"> <li>• Hepatitis B vaccine</li> </ul>  |
| Neonatal Intensive Care Unit or Specialist Care Baby Unit admission more than 3 days  | <ul style="list-style-type: none"> <li>• Tdap for parents/primary caregivers if maternal Tdap not given at least 14 days before birth</li> </ul>               |
| Pneumococcal disease – increased risk   | <ul style="list-style-type: none"> <li>• Additional pneumococcal vaccines</li> </ul>   |
| Pregnancy <small>IMAC fact sheet available</small>  | <ul style="list-style-type: none"> <li>• Influenza and Tdap vaccines in every pregnancy</li> </ul>   |
| Solid organ transplantation <small>IMAC fact sheet available</small>  |  |
| » Prior to solid organ transplantation  | <ul style="list-style-type: none"> <li>• Hepatitis A, hepatitis B, Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul>                   |
| » Following solid organ transplantation   | <ul style="list-style-type: none"> <li>• Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines</li> </ul>              |
| Tuberculosis – infants and children aged under 5 years at risk of tuberculosis (TB) exposure  | <ul style="list-style-type: none"> <li>• BCG vaccine</li> </ul>  |

**Vaccine key** – BCG: tuberculosis; Hib: *Haemophilus influenzae* type b; HPV: human papillomavirus; IPV: inactivated polio vaccine; Tdap: tetanus, diphtheria, acellular pertussis.

| Vaccine   | Individuals eligible for funded vaccine  |
|---|--|
| <i>Haemophilus influenzae</i> type b (Hib) vaccine                                    | <ul style="list-style-type: none"> <li>An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen longer than 28 days</li> </ul>  |
| Hepatitis A vaccine   | <ul style="list-style-type: none"> <li>One dose for close contacts of a hepatitis A case</li> <li>Two doses for transplant patients; or children with chronic liver disease</li> </ul>   |
| Hepatitis B vaccine or<br>Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG)   | <ul style="list-style-type: none"> <li>Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; children aged under 18 years who are considered not to have achieved a positive serology and require additional vaccination; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy; non-consensual sexual intercourse; or needle stick injury (20mcg/mL for infants, children and adults)</li> <li>Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg from coadministration of two 20mcg/mL doses)</li> </ul>   |
| Human papillomavirus (HPV) vaccine  | <ul style="list-style-type: none"> <li>Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive</li> <li>A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy</li> </ul>   |
| Influenza vaccine   | <ul style="list-style-type: none"> <li>Pregnant women in every pregnancy during vaccination season</li> <li>Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness</li> <li>Individuals aged 65 years and older</li> <li>Individuals aged 6 months to under 65 years with certain medical conditions, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation</li> </ul>   |
| Meningococcal B vaccine   | <p><b>Aged under 12 months</b></p> <ul style="list-style-type: none"> <li>Up to three doses as appropriate for infants who have previously had meningococcal disease of any group or who are a close contact of a meningococcal disease case of any group; post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> </ul> <p><b>Aged 12 months or older</b></p> <ul style="list-style-type: none"> <li>Up to two doses for individuals who have previously had meningococcal disease of any group or who are a close contact of a meningococcal disease case of any group; post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> <li>One booster dose every five years for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional or anatomic asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> </ul>  |
| Meningococcal C vaccine and/or<br>Meningococcal A,C,Y,W vaccine<br><br><b>UPDATED</b> | <p><b>Aged under 9 months – MenCCV</b></p> <ul style="list-style-type: none"> <li>Up to three doses as appropriate for infants pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> <li>Two doses for infants who have previously had meningococcal disease of any group or who are a close contact of a meningococcal disease case of any group; post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days</li> </ul> <p><b>Aged 9 months or older – MenACYW-D</b></p> <ul style="list-style-type: none"> <li>One dose for individuals who have previously had meningococcal disease of any group or who are a close contact of a meningococcal disease case of any group</li> <li>One dose for individuals aged 13–25 years inclusively who are entering within the next 3 months, or in their first year of living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison</li> <li>To 30 November 2021, one dose for individuals aged 13–25 years inclusively who are in their second, third or more years living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison</li> <li>Two doses for individuals post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days</li> <li>Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> </ul> |

Continued on next page ...

| Vaccine   | Individuals eligible for funded vaccine  |
|---|--|
| Pneumococcal conjugate (PCV13) vaccine  | <p><b>Infants and children aged under 5 years – up to four age-appropriate doses, and Children aged 12 months to under 18 years who have previously received two doses of PCV10 – up to two doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</li> </ul> <p><b>Children aged 5 years or older, and adults – up to four age-appropriate doses</b></p> <ul style="list-style-type: none"> <li>Pre- or post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</li> </ul> |
| Pneumococcal polysaccharide (23PPV) vaccine   | <p><b>Children aged 2 years to under 18 years – up to two doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</li> </ul> <p><b>Adults aged 18 years or older – up to three doses (as appropriate)</b></p> <ul style="list-style-type: none"> <li>Post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</li> </ul>  |
| Tetanus, diphtheria and pertussis (Tdap) vaccine  | <ul style="list-style-type: none"> <li>One dose for pregnant women, in the second or third trimester of every pregnancy</li> <li>One dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days and whose mother did not receive maternal Tdap at least 14 days prior to birth</li> </ul> <p>» Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen</p>   |
| Tuberculosis BCG vaccine  | <p><b>Infants and children aged under 5 years</b></p> <ul style="list-style-type: none"> <li>Living in a house or family with a person with current or past history of tuberculosis (TB), or</li> <li>Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB at 40/100,000 or greater for 6 months or longer, or</li> <li>During their first 5 years will be living 3 months or longer in a country with a rate of TB 40/100,000 or greater</li> </ul>  |
| <p>Varicella vaccine</p> <ul style="list-style-type: none"> <li>From age 12 months in primary care</li> <li>From age 9 months in secondary/hospital care</li> </ul> | <p><b>Two doses for non-immune individuals:</b></p> <ul style="list-style-type: none"> <li>Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist</li> <li>Prior to elective immunosuppressive therapy that will be longer than 28 days</li> <li>With chronic liver disease who may in future be candidates for transplantation</li> <li>With deteriorating renal function before transplantation</li> <li>Pre-solid organ transplantation</li> <li>Post-chemotherapy; post-haematopoietic stem cell transplantation, on the advice of their specialist</li> <li>Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis</li> </ul> <p><b>Two doses for individuals with no clinical history of varicella infection or immunisation:</b></p> <ul style="list-style-type: none"> <li>With an inborn error of metabolism at risk of major metabolic decompensation</li> <li>Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection of immunisation</li> <li>Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation</li> </ul>                   |